All articles tagged with #gip
BlackRock's Global Infrastructure Partners (GIP) is in negotiations for a nearly $40 billion data centre deal, highlighting significant investment activity in the data infrastructure sector.
Global Infrastructure Partners is in advanced negotiations to acquire Aligned Data Centers for about $40 billion, a deal that highlights the booming interest in AI infrastructure investments, with involvement from Mubadala and potential expansion into other sectors like power utilities. The transaction, if finalized, would be among the largest this year, reflecting the surge in data center and AI-related infrastructure spending amid concerns over market bubbles and demand sustainability.
BlackRock's Global Infrastructure Partners is nearing a $38 billion deal to acquire utility company AES, driven by increased power demand from AI and data center growth. AES stock surged over 14% on the news, breaking out above a key buy point, while BlackRock's shares also gained in 2025.
A landmark study over a decade ago suggested a new approach to treating obesity and diabetes by activating gut hormone receptors GLP-1 and GIP. This approach was used by Eli Lilly to develop tirzepatide, a medicine for diabetes and weight loss. However, recent research has raised questions about the effectiveness of GIP in treating obesity, leading to conflicting views within the scientific community.
Glucose-dependent insulinotropic polypeptide (GIP) regulates body weight and food intake through GABAergic neurons, according to a study in mice. The study found that GIPR agonism is a vital component of GIPR-GLP-1R co-agonism, which has been effective in treating obesity and diabetes. Mice with Gipr deletion in inhibitory GABAergic neurons showed decreased body weight, improved glucose metabolism, and decreased food intake. The study also revealed that GIP acts on hindbrain GIPR neurons to regulate food intake, and GIP requires GIPR signaling in inhibitory GABAergic neurons to decrease food intake. These findings provide insights into the mechanisms underlying the metabolic effects of GIP and GIPR-GLP-1R co-agonism.
Viking Therapeutics' experimental obesity treatment, which activates hormones GLP-1 and GIP, resulted in patients losing up to 18 pounds and caused the company's stock to soar to a five-year high. The drug's weight-loss effect appears durable and the majority of side effects were mild or moderate. Viking plans to test an oral version of the drug, which could be an alternative to weekly injections. The company is competing against Novo Nordisk and Eli Lilly in the burgeoning obesity treatment market.
Viking Therapeutics has initiated a Phase 1 clinical study to evaluate an oral formulation of its dual GLP-1/GIP receptor agonist VK2735. The study will evaluate daily oral doses for 28 days and the results are expected to be available in the second half of 2023. The primary objective of the study is to evaluate the safety and tolerability of VK2735 administered as an oral tablet once daily for 28 days. The secondary objective is to evaluate the pharmacokinetics of orally administered VK2735 in healthy subjects.
Researchers in Greenville are conducting clinical trials on a GLP-GIP combination drug, similar to the diabetic drug Ozempic, that has been shown to help reduce weight. The drug works in combination with another gut hormone called GIP, which helps control blood sugar levels and appetite. The combination of hormones could be more effective for weight loss. The drug is currently only approved for diabetes, not weight loss. Common side effects include gastrointestinal pain or discomfort. Only diabetic patients who meet certain criteria can enroll in the clinical trial.